ValiRx PLC Live Shareholder Q&A and Investor presentations
11 Noviembre 2021 - 01:00AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
11 November 2021
11 November 2021
ValiRx PLC ("ValiRx" or the "Company")
Live Shareholder Q&A and Investor presentations
Live Q&A: London, UK - ValiRx Plc (AIM: VAL), a life science
company focusing on early-stage cancer therapeutics and women's
health, invites shareholders to join the CEO, Chairman and
Corporate Development Manager in a Zoom webinar on 25 November 2021
at 2pm (UK). Registration prior to the event is recommended to
ensure all notifications about the webinar are received by
participants. Registration details will be available on the ValiRx
website closer to the event. The format will comprise a short
presentation by the Company on latest developments, followed by an
invitation to shareholders to activate their cameras and speak
directly with the ValiRx team. A recording of the event will be
available to view from the ValiRx website shortly after the event
concludes.
LSE Investor Presentation: CEO, Dr Suzy Dilly will also be
presenting at this event on the evening of 7 December (6pm - 8pm
(UK)). Prior registration is required directly with LSE, which can
be accessed at
https://us02web.zoom.us/webinar/register/1116364722800/WN_oBS-LVJrQJ-K9iQlDe3nMA.
The format will be a short presentation and audience Q&A.
Corporate Update: The Company is also pleased to inform
shareholders that the entry on www.clinicaltrials.gov for the
recently completed VAL201 clinical trial has now been finalised
with the addition of a summary of raw data results.
Dr Suzy Dilly, CEO of ValiRx commented: "I am looking forward to
joining our shareholders in further live discussions as we continue
building our events schedule to achieve transparent shareholder
communications. Further conversations about our recent scientific
and commercial advances, as well as conversations around our
emerging strategy in Women's Health are important as we wish to
ensure that shareholders understand how we are intending to
continue to build long term value into the Company."
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476
Dr Suzanne Dilly, CEO 796496
www.valirx.com
Suzanne.Dilly@valirx.com
Cenkos Securities Limited (Broker) Tel: +44 (0) 20 7397
Russell Kerr/Michael Johnson (Sales) 8900
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Notes for Editors
About ValiRx
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZMMMGGDGMZZ
(END) Dow Jones Newswires
November 11, 2021 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024